About Us

EIR Biopharma, Inc. is a preclinical stage biotech company developing therapeutics targeting the Ephrin receptor. Our initial therapeutic development efforts center on targeting the Ephrin receptor for the treatment of eye disease.

We have partnered with the University of Miami’s Bascom Eye Institute and the Weill Cornell Medical College of Cornell University. 

Our founders have over 50 years of senior-level management experience in the biotechnology, pharmaceutical, and biopharma industries, and have helped to create publicly traded biopharma companies with peak market capitalizations exceeding $15 billion and FDA approved drugs.

To learn more about EIR Biopharma, you can view our company presentation here: